格隆汇3月31日丨赣锋锂业(01772.HK)发布公告，张启昌已辞任公司秘书、授权代表及法律程序文件代 理人，自2026年3月30日起生效。 廖轶琳及温咏宜已获委任为联席公司秘书，自2026年3月30日起生效。此外，温咏宜已获委任为授权代 表及法律程序文件代理人，自2026年3月30日起生效。 ...

Core Viewpoint - Ganfeng Lithium (01772.HK) announced the nomination of Liu Chongliang as an independent non-executive director candidate, pending approval by the shareholders' meeting [1] Group 1 - The board of Ganfeng Lithium has agreed to nominate Liu Chongliang for the position of independent non-executive director [1] - Liu's term will begin upon his election by the shareholders and will align with the term of the sixth board, excluding consecutive re-elections [1] - The appointment of Liu as an independent non-executive director is subject to approval at the company's shareholders' meeting [1]

Core Viewpoint - The property management industry is shifting its focus from scale growth to sustainable cash flow generation and independent operational capabilities as it transitions from a growth phase to a stock game phase [1][12]. Group 1: Company Performance - Shimao Services reported a revenue of 7.88 billion yuan in 2025, reflecting a strategic shift towards quality and efficiency rather than mere scale [3]. - The property management service revenue grew by 4.7% year-on-year to 5.82 billion yuan, accounting for 73.8% of total revenue, with 71.2% of managed area coming from independent third-party projects [4][5]. - The company achieved a gross profit of 1.4 billion yuan and an operating profit of 162 million yuan, marking a significant turnaround from a loss of 158 million yuan in 2024 [6]. Group 2: Revenue Structure - The company’s diversified revenue structure includes community value-added services, non-owner value-added services, and urban services, contributing to overall income stability [5]. - Community value-added service revenue reached 1.32 billion yuan, up 9.5% year-on-year, with the elderly care business achieving 216 million yuan in revenue, a 15.2% increase [9]. - The urban services segment generated 542 million yuan, with a 137.2% increase when excluding the impact of a divested subsidiary [11]. Group 3: Growth Strategies - The company is expanding its non-residential business, with a 44.7% increase in newly added non-residential property contract area, reaching 35.2% of total managed area [8]. - The company focuses on high-quality project selection, with 85.4% of managed properties located in first-tier and new first-tier cities, ensuring sustainable revenue growth [14][15]. - The company’s strategic emphasis on operational efficiency led to a 15.7% reduction in administrative expenses, reflecting a commitment to cost management while expanding business scale [16]. Group 4: Industry Context - The property management industry is undergoing a structural transformation, with a shift from reliance on real estate developers to independent operational capabilities [12][13]. - The market is increasingly valuing cash flow quality and service capabilities over mere scale, indicating a fundamental change in investor sentiment [13][17]. - Shimao Services is positioned to benefit from this industry trend, with a clear growth path and improved profitability metrics [17].

Core Viewpoint - The company is expected to achieve strong revenue and profit growth in 2025, with total revenue projected at 13.042 billion yuan, a year-on-year increase of 38.4%, and product revenue at 11.896 billion yuan, up 44.6% [1][2] - The company has established significant partnerships with Roche, Takeda, and Eli Lilly, highlighting its strong R&D capabilities and increasing international recognition [1] - The company is becoming a leading pharmaceutical enterprise in China, with a competitive global innovation pipeline, and aims to become a world-class biopharmaceutical company [1] Financial Performance - In 2025, the company reported total revenue of 13.042 billion yuan, a 38.4% increase year-on-year, with product revenue reaching 11.896 billion yuan, up 44.6% [1] - The company achieved a turnaround in IFRS net profit, reporting 814 million yuan in 2025, a significant improvement from a loss of 95 million yuan in 2024, driven by strong revenue growth and improved operational efficiency [1] - Non-IFRS net profit for 2025 was 1.723 billion yuan, a substantial increase from 332 million yuan in 2024, with EBITDA reaching 1.99 billion yuan, up from 412 million yuan in 2024 [1] Commercialization and Product Development - The company has built a leading oncology brand in China and is developing a rising chronic disease innovation brand, with a comprehensive product portfolio and a mature commercialization network [2] - The product portfolio has expanded to 18 products, with 12 included in the national medical insurance, covering oncology, metabolism, and autoimmune diseases [2] - The company’s product revenue of 11.896 billion yuan in 2025 marks its first breakthrough of 10 billion yuan, reflecting the foresight and efficient commercialization execution, with expectations to exceed 20 billion yuan in product revenue by 2027 [2]

Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company's revenue for the fiscal year was 14.095 billion RMB, showing a growth of 14.82% compared to the previous year [1] - The net profit attributable to shareholders was 1.664 billion RMB, which is a decrease of 7.2% year-on-year [1] - The board proposed a final dividend of 2.0 RMB per 10 shares (before tax) for the year ending December 31, 2025 [1] Group 2: Strategic Initiatives - The company is deepening its customer-centric service philosophy and leveraging a fully integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding strategic customer relationships, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, resulting in rapid growth in client business [1] Group 3: Future Outlook - The company expects a year-on-year growth of over 14% in new signed orders for 2025 [1] - Based on new orders and business trends, the company anticipates a revenue growth of 12% to 18% for the year 2026 [1]

Core Viewpoint - Anhui Wantuo Expressway (00995.HK) has made a strategic investment by purchasing a total of 24,262,729 shares of Shenzhen Expressway A-shares and 31,010,000 shares of Shenzhen Expressway H-shares, indicating a commitment to enhancing its investment portfolio in the toll road sector [1] Group 1: Investment Details - The total purchase price for the A-shares was approximately RMB 222,784,481.64 (around HKD 252,064,266.88) and for the H-shares was approximately RMB 206,014,349.92 (around HKD 233,090,095.40), excluding transaction costs [1] - The payment for the shares was made using the company's internal cash resources [1] Group 2: Strategic Implications - This acquisition represents a continuation of the company's strategic investment in leading toll road operators, which is expected to facilitate potential collaboration and synergies with Shenzhen Expressway [1] - The investment will allow the company to benefit from Shenzhen Expressway's diversified highway portfolio, which is located outside of Anhui Province, contrasting with the company's primary operations in Anhui [1] - The acquisition is viewed as an attractive investment opportunity, leveraging Shenzhen Expressway's asset quality, stable financial performance, and long-term value to achieve returns [1]

Core Viewpoint - Anhui Wantuo Expressway (00995.HK) has made a strategic investment by purchasing a total of 24,262,729 shares of Shenzhen Expressway A-shares and 31,010,000 shares of Shenzhen Expressway H-shares, indicating a commitment to enhancing its investment portfolio in the toll road sector [1] Group 1: Investment Details - The total purchase price for the A-shares was approximately RMB 222,784,481.64 (around HKD 252,064,266.88) and for the H-shares was approximately RMB 206,014,349.92 (around HKD 233,090,095.40), excluding transaction costs [1] - The payment for the shares was made using the company's internal cash resources [1] Group 2: Strategic Implications - This acquisition represents a continuation of the company's strategic investment in leading toll road operators, which is expected to facilitate potential collaboration and synergies with Shenzhen Expressway [1] - The investment will allow the company to benefit from Shenzhen Expressway's diversified toll road portfolio, which extends beyond Anhui province, where the company primarily operates [1] - The acquisition is viewed as an attractive investment opportunity, leveraging Shenzhen Expressway's asset quality, stable financial performance, and long-term value to achieve returns [1]

Group 1 - The core announcement is the nomination of Mr. Zhou Fengyuan as a non-executive director of Zhaoyan New Drug (06127.HK), pending approval by shareholders at the annual general meeting [1] - The company projects a significant increase in net profit attributable to shareholders, forecasting a net profit of 299 million yuan for 2025, representing a substantial year-on-year growth of 302.1% [1]

Core Viewpoint - Shenzhou Holdings (00861.HK) reported a significant turnaround in its financial performance for the fiscal year 2025, with a revenue of RMB 21.015 billion, marking a 26% increase year-on-year, and a net profit of RMB 31.42 million, recovering from a loss of RMB 254 million in the previous year [1] Financial Performance - The company achieved a revenue of RMB 21.015 billion, which is a 26% increase compared to the same period last year [1] - The net profit attributable to shareholders turned from a loss of RMB 254 million to a profit of RMB 31.42 million [1] - Basic earnings per share were reported at RMB 0.0212, with a proposed final dividend of HKD 0.036 per ordinary share [1] Operational Highlights - The improvement in operational quality was driven by strong marketing and lean operations, leading to rapid growth in integrated supply chain services [1] - The fintech services segment also turned profitable during the reporting period [1] - The company reported a net cash flow from operating activities of RMB 490 million, with new contracts signed amounting to RMB 16.19 billion, establishing a solid foundation for long-term and stable growth [1] Service-Oriented Business - The company introduced a new "service-oriented business" segment, which leverages integrated supply chain services and data intelligence technology to deliver high-value services such as end-to-end fulfillment, e-commerce operations, and digital empowerment [1] - Revenue from the service-oriented business reached RMB 10.14 billion, representing a 9% increase year-on-year and accounting for 48% of the group's total revenue [1]

格隆汇3月30日丨民生银行(600016.SH)发布2025年年报显示，公司全年实现营业收入1428.65亿元，同比 增长4.82%；归母净利润305.63亿元，同比下滑5.37%；扣非归母净利润309.26亿元，同比下滑4.19%。 对全体股东10派0.53元。 ...